Abreos Biosciences Announces Research Collaboration with FDA-CDER

Tuesday, March 26, 2019 Research News
Email Print This Page Comment bookmark
Font : A-A+

Precision dosing leader Abreos Biosciences enters research collaboration with FDA's Center for Drug Evaluation and Research (CDER) to develop several drug concentration measurement assays based on the Veritope™ platform.

SAN DIEGO, Mar. 26, 2019 /PRNewswire-PRWeb/ -- Abreos Biosciences, a San Diego-based

biotech company and leader in precision dosing of biological therapeutics, is pleased to announce a research collaboration with the FDA's Center for Drug Evaluation and Research (CDER) to develop several methods to measure the drug concentration of biologic drugs based on the Veritope™ platform. With this platform, Abreos rapidly produces sensitive and specific custom reagents that are easily adapted to different assay platforms, including in clinical trials.

"Biologics are among the most powerful therapeutics available for many serious diseases, but there is enormous inter-patient variability in their pharmacokinetics. Standard one-size-fits-all dosing paradigms are clearly not optimal, and we hope that our simple and deployable drug monitoring tests can be used in clinical trials and enable personalized, precision dosing. We are excited to work with CDER on testing this novel technology." said Bradley Messmer, Ph.D., CEO and founder of Abreos.

The overarching goal of this collaborative research between FDA CDER and Abreos Biosciences is to study and evaluate novel methodologies for bioanalytical measurements of biologics & biosimilars. The FDA requires the use of methods that can be developed and validated rapidly to respond to urgent regulatory needs. Additionally, the methodology developed from this research will be applied to FDA-sponsored studies to characterize pharmacokinetic-pharmacodynamic effects of drugs.

It is hoped by both sides that the use of the novel technology for determining concentration of biological drugs can result in more efficient pathways for ensuring the safety and efficacy of human drugs.

For additional information please go to http://www.abreos.com or contact info(at)abreosbio(dot)com.

 

SOURCE Abreos Biosciences



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store